Groundbreaking Computational Tool Revolutionises Personalised Cancer Treatment
In a significant leap forward in cancer treatment, scientists at the Ludwig Institute for Cancer Research have unveiled NeoDisc, a comprehensive computational pipeline that integrates a multitude of molecular and genetic analyses. Utilising artificial intelligence algorithms, NeoDisc precisely designs personalised cancer vaccines for patients, potentially revolutionising cancer immunotherapy. The findings, led by Florian Huber and Michal Bassani-Sternberg from the Lausanne Branch, are published in the 2024 edition of Nature Biotechnology.
NeoDisc is described as a transformational tool in understanding tumour immunobiology, particularly in how cancers evade detection by the immune system's cytotoxic T cells. This new computational suite provides unparalleled insight and is already being applied in clinical trials for personalised cancer vaccines and adoptive cell therapies in Lausanne.
Tumours with random mutations often generate proteins that are abnormally presented as antigens, ideally marking them for destruction by T cells. However, the variability in how patients respond to such immunotherapies is due to the great diversity of these neoantigens. By leveraging this diversity, personalised treatments are being developed globally to specifically target tumour types in individual patients.
The technical challenge lies in identifying which neoantigens effectively elicit strong immune responses, as many do not automatically provoke an adequate T cell response. NeoDisc addresses this complex issue through extensive analyses of mutations, the molecular scaffolds that present neoantigens, and the molecular traits recognized by T cell receptors. This process, known as "immunopeptidomics," combines large-scale biochemical and computational analyses.
The advancement presents a unified approach where sophisticated technologies predict which neoantigens can be employed in personalised immunotherapies. It covers beyond neoantigens to include aberrant protein expressions and viral antigens in some tumours, expanding the scope of immunotherapeutic targeting.
Dr Michal Bassani-Sternberg notes NeoDisc's capability to detect a wide range of tumour-specific antigens, using machine learning to prioritise targets likely to trigger a robust T cell response. Moreover, NeoDisc identifies potential defects in antigen presentation, offering valuable insights into immune evasion strategies of tumours, thus aiding clinicians in patient selection for clinical studies to improve immunotherapy outcomes.
NeoDisc surpasses existing computational tools in accurately selecting effective antigens for vaccines and adoptive cell therapies. Future refinements to NeoDisc will include further data integration and enhanced machine-learning algorithms to improve its predictive precision, ensuring its position at the forefront of personalised cancer treatment technology.
Source: Noah Wire Services